Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.
Zarranz-Ventura J, Parrado-Carrillo A, Nguyen V, Sararols L, Garay-Aramburu G, Puzo M, Arruabarrena C, Figueras-Roca M, Gillies MC, Casaroli-Marano RP; from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Zarranz-Ventura J, et al. Clin Exp Ophthalmol. 2022 Apr;50(3):312-324. doi: 10.1111/ceo.14054. Epub 2022 Feb 20. Clin Exp Ophthalmol. 2022. PMID: 35106882 Free article.
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A; In-Eye Study Group. Saenz-de-Viteri M, et al. Acta Ophthalmol. 2021 Dec;99(8):861-870. doi: 10.1111/aos.14786. Epub 2021 Mar 15. Acta Ophthalmol. 2021. PMID: 33720541 Free article. Clinical Trial.